BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 29277775)

  • 1. Novel Metabolically Stable PCA-1/ALKBH3 Inhibitor Has Potent Antiproliferative Effects on DU145 Cells
    Ueda M; Shimizu T; Mabuchi M; Horiike K; Kitae K; Hase H; Ueda Y; Tsujikawa K; Tanaka A
    Anticancer Res; 2018 Jan; 38(1):211-218. PubMed ID: 29277775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving the bioavailability and anticancer effect of the PCA-1/ALKBH3 inhibitor HUHS015 using sodium salt.
    Mabuchi M; Shimizu T; Ueda M; Sasakawa Y; Nakao S; Ueda Y; Kawamura A; Tsujikawa K; Tanaka A
    In Vivo; 2015; 29(1):39-43. PubMed ID: 25600528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of prostate cancer antigen-1 (PCA-1/ALKBH3) inhibitors as anti-prostate cancer drugs.
    Nakao S; Mabuchi M; Shimizu T; Itoh Y; Takeuchi Y; Ueda M; Mizuno H; Shigi N; Ohshio I; Jinguji K; Ueda Y; Yamamoto M; Furukawa T; Aoki S; Tsujikawa K; Tanaka A
    Bioorg Med Chem Lett; 2014 Feb; 24(4):1071-4. PubMed ID: 24461353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. anti-tumor effect of AlkB homolog 3 knockdown in hormone- independent prostate cancer cells.
    Koike K; Ueda Y; Hase H; Kitae K; Fusamae Y; Masai S; Inagaki T; Saigo Y; Hirasawa S; Nakajima K; Ohshio I; Makino Y; Konishi N; Yamamoto H; Tsujikawa K
    Curr Cancer Drug Targets; 2012 Sep; 12(7):847-56. PubMed ID: 22515525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ALKBH3, a human AlkB homologue, contributes to cell survival in human non-small-cell lung cancer.
    Tasaki M; Shimada K; Kimura H; Tsujikawa K; Konishi N
    Br J Cancer; 2011 Feb; 104(4):700-6. PubMed ID: 21285982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Indenone derivatives as inhibitor of human DNA dealkylation repair enzyme AlkBH3.
    Nigam R; Babu KR; Ghosh T; Kumari B; Akula D; Rath SN; Das P; Anindya R; Khan FA
    Bioorg Med Chem; 2018 Aug; 26(14):4100-4112. PubMed ID: 30041948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PCA-1/ALKBH3 contributes to pancreatic cancer by supporting apoptotic resistance and angiogenesis.
    Yamato I; Sho M; Shimada K; Hotta K; Ueda Y; Yasuda S; Shigi N; Konishi N; Tsujikawa K; Nakajima Y
    Cancer Res; 2012 Sep; 72(18):4829-39. PubMed ID: 22826605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glutamine deficiency induces DNA alkylation damage and sensitizes cancer cells to alkylating agents through inhibition of ALKBH enzymes.
    Tran TQ; Ishak Gabra MB; Lowman XH; Yang Y; Reid MA; Pan M; O'Connor TR; Kong M
    PLoS Biol; 2017 Nov; 15(11):e2002810. PubMed ID: 29107960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The STAT3 Inhibitor Galiellalactone Effectively Reduces Tumor Growth and Metastatic Spread in an Orthotopic Xenograft Mouse Model of Prostate Cancer.
    Canesin G; Evans-Axelsson S; Hellsten R; Sterner O; Krzyzanowska A; Andersson T; Bjartell A
    Eur Urol; 2016 Mar; 69(3):400-4. PubMed ID: 26144873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AlkB homolog 3-mediated tRNA demethylation promotes protein synthesis in cancer cells.
    Ueda Y; Ooshio I; Fusamae Y; Kitae K; Kawaguchi M; Jingushi K; Hase H; Harada K; Hirata K; Tsujikawa K
    Sci Rep; 2017 Feb; 7():42271. PubMed ID: 28205560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic Trial for Evaluating Docetaxel in a Human Prostate Cancer Cell DU145 Xenograft Model.
    Mabuchi M; Ueda M; Yoshida Y; Horiike K; Yamaoka K; Nakao S; Shimizu T; Ueda Y; Tsujikawa K; Tanaka A
    Anticancer Res; 2017 Apr; 37(4):1665-1676. PubMed ID: 28373427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.
    Handratta VD; Vasaitis TS; Njar VC; Gediya LK; Kataria R; Chopra P; Newman D; Farquhar R; Guo Z; Qiu Y; Brodie AM
    J Med Chem; 2005 Apr; 48(8):2972-84. PubMed ID: 15828836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA unwinding by ASCC3 helicase is coupled to ALKBH3-dependent DNA alkylation repair and cancer cell proliferation.
    Dango S; Mosammaparast N; Sowa ME; Xiong LJ; Wu F; Park K; Rubin M; Gygi S; Harper JW; Shi Y
    Mol Cell; 2011 Nov; 44(3):373-84. PubMed ID: 22055184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Docetaxel induces Bcl-2- and pro-apoptotic caspase-independent death of human prostate cancer DU145 cells.
    Ogura T; Tanaka Y; Tamaki H; Harada M
    Int J Oncol; 2016 Jun; 48(6):2330-8. PubMed ID: 27082738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.
    Ma JG; Huang H; Chen SM; Chen Y; Xin XL; Lin LP; Ding J; Liu H; Meng LH
    Breast Cancer Res Treat; 2011 Nov; 130(1):85-96. PubMed ID: 21181437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Synergic effects of the combination of VEGF-targeted shRNA and taxol on human prostate cancer DU145 both in vitro and in vivo].
    Li BW; Zhang M; He HW; Zhang SH; Shao RG
    Yao Xue Xue Bao; 2009 Mar; 44(3):296-302. PubMed ID: 19449527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ALKBH3 contributes to survival and angiogenesis of human urothelial carcinoma cells through NADPH oxidase and tweak/Fn14/VEGF signals.
    Shimada K; Fujii T; Tsujikawa K; Anai S; Fujimoto K; Konishi N
    Clin Cancer Res; 2012 Oct; 18(19):5247-55. PubMed ID: 22850567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.
    Li X; Wu JB; Chung LW; Huang WC
    Oncotarget; 2015 Dec; 6(38):41018-32. PubMed ID: 26512780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel PI3K inhibitor displays potent preclinical activity against an androgen-independent and PTEN-deficient prostate cancer model established from the cell line PC3.
    Shi M; Zhou X; Zhang Z; Wang M; Chen G; Han K; Cao B; Liu Z; Mao X
    Toxicol Lett; 2014 Aug; 228(3):133-9. PubMed ID: 24831963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
    Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
    Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.